IMAC Holdings, trading under the ticker BACK, has been capturing attention with its current stock price at
1.23 in the Medical Care Facilities industry. Despite facing challenges like a significant free cash flow loss of
2.8M, investors are keen to see if the company can turn the tide and offer potential gains this November.
Main Ideas
By examining the fundamental indicators of IMAC Holdings and Assure, you can assess how market fluctuations impact their stock prices and determine if combining them in your portfolio could reduce risk. Pair trading strategies might be useful, such as going long on Assure while shorting IMAC Holdings. For more insights, explore our [pair correlation module](#) for detailed analysis.
Now, let's delve into asset utilization. This metric shows how much revenue a company generates per dollar of assets. IMAC Holdings boasts an impressive asset utilization ratio of 454.24%, meaning it earns $4.54 for every dollar of assets. This high ratio indicates that IMAC Holdings is effectively leveraging its assets to boost operational efficiency.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as IMAC or Novo is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is IMAC Holdings's Liquidity
IMAC Holdings
financial leverage refers to using borrowed capital as a funding source to finance IMAC Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. IMAC Holdings financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to IMAC Holdings' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of IMAC Holdings' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between IMAC Holdings's total debt and its cash.
Correlation Between IMAC and Novo Integrated Sciences
In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding IMAC Holdings together with similar or unrelated positions with a negative correlation. For example, you can also add Novo Integrated to your portfolio. If Novo Integrated is not perfectly correlated to IMAC Holdings it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When IMAC Holdings, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both IMAC Holdings and Novo Integrated in your portfolio? Please note if you are using this as a pair-trade strategy between IMAC Holdings and Novo Integrated, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between BACK and NVOS for more information.
Is IMAC Holdings valued adequately by the market?
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Let me now analyze IMAC Holdings revenue. Based on the latest financial disclosure, IMAC Holdings reported 5.2
M of revenue.
This is 99.93% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the
Health Care industry. The revenue for all United States stocks is 99.94% higher than that of the company. As for Assure Holdings we see revenue of 255
K, which is much higher than that of the Health Care
| BACK | 5.2 Million | 95.32 |
| Sector | 0.0 | 0.0 |
| IONM | 255,000 | 4.68 |
"Fortune favors the bold" is a saying that resonates with investors considering IMAC Holdings (BACK) this November. With a market capitalization of just $1.81 million and a high probability of bankruptcy at 96%, the stock presents both significant risk and potential reward. Despite its challenges, including a quarterly revenue growth decline of 59% and a negative EBITDA of 1.7 million, the company's low beta of 0.25 suggests limited volatility compared to the broader market. Investors with a high-risk tolerance might find the potential upside of 10.49 intriguing, especially given the Wall Street target price of $8.25, which indicates substantial room for growth. However, caution is advised, as the company's financial health remains precarious, underscored by a negative return on equity of 3.32 and a current ratio of 1.18X, reflecting its struggle to cover short-term liabilities..
Our take on today IMAC Holdings rise
Today, IMAC Holdings experienced a significant uptick, drawing investor interest. However, the recent drop in Jensen's Alpha to -0.43 raises some concerns. This figure indicates that the stock might not be performing as well as the broader market, suggesting a potential price decline. While today's rise is promising, investors should remain vigilant and factor in this metric when assessing their positions in IMAC Holdings. The stock shows low volatility, with a skewness of -0.18 and kurtosis of 3.29.
Understanding these volatility trends can help investors make informed decisions. During bear markets, increased volatility can affect IMAC Holdings' stock price, prompting investors to adjust their portfolios by diversifying as prices decrease.Considering the current market dynamics and the strong analyst consensus around IMAC Holdings, it appears to be a promising opportunity for investors. With an analyst target price estimated value of 34.5, the stock holds potential for significant appreciation. Although the EPS estimate for next year is -3.48, the overall sentiment remains optimistic, as evidenced by the strong buy recommendations. This suggests that the market may be undervaluing the company's future prospects. Given these insights, now might be an opportune moment to explore IMAC Holdings as a potential addition to your portfolio, especially if you're looking to capitalize on growth opportunities in the healthcare sector..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of IMAC Holdings. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]